Developability and CMC at Antibody Engineering 2026

Dec 13–16, 2026 San Diego, CA ~900 attendees Website

36 organizations at Antibody Engineering 2026 present work in developability & CMC: 23 suppliers and service providers, 11 drug developers and 2 academic, government and non-profit bodies. Between them they bring 41 presentations to the program. Most represented: Xencor (4 on the program), Amgen (3 on the program), Johnson & Johnson (3 on the program). As of Nov 10, 2026.

All 168 organizations at Antibody Engineering 2026 →

Format
Top represented
Showing 1–12 of 36 organizations
OrganizationAntibody Engineering 2026 Attendance
Xencor
Pasadena, CA
Biotech
Develops engineered antibodies using its XmAb Fc and bispecific technologies, for cancer and autoimmune diseases.
Chair
Sun Dec 13
1:00pm–1:15pm
Co-Chairs' Remarks: From Discovery to IND: What Matters Most and How to Get it Right
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Amgen
Talk
Sun Dec 13
4:15pm–5:00pm
Moderated Panel Discussion with Session Speakers
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Amgen
Chair
Mon Dec 14
8:00am–8:05am
Co-Chairs' Welcome and Opening Remarks
Keynote Presentations - Livestream · with Gyes
Talk
Mon Dec 14
10:55am–11:30am
Jim Huston Science Talent Award and Presentation
Keynote Presentations - Livestream · with Dana-Farber Cancer Institute, Johnson & Johnson
Chair
Wed Dec 16
8:10am–8:15am
Co-Chairs’ Remarks
Track 2: Engineering Antibody Interfaces: Unlocking New Biology · with Dualitas Therapeutics
Talk
Wed Dec 16
9:15am–9:45am
XenLock™ Fab domains for controlled heavy-light chain pairing in native-like 1+1 bispecific antibodies with extended half-life
Redesigned antibody arms that pair only with their intended partner, used to build two-target antibodies that last longer in blood.
Bispecifics & multispecifics
Amgen
Thousand Oaks, CA
Large pharma
Global biopharmaceutical company developing and manufacturing biologic medicines, including bispecific T-cell engagers.
Chair
Sun Dec 13
1:00pm–1:15pm
Co-Chairs' Remarks: From Discovery to IND: What Matters Most and How to Get it Right
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Xencor
Talk
Sun Dec 13
1:15pm–1:45pm
Developability-Guided Generative Biology for Therapeutic Protein Engineering
Designing new therapeutic proteins by computer while checking from the start that they can be made and purified.
AI & computational design
Talk
Sun Dec 13
4:15pm–5:00pm
Moderated Panel Discussion with Session Speakers
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Xencor
Talk
Mon Dec 14
5:45pm–6:15pm
Induced Proximity and Next-Generation Antibody Therapeutics
Track 2: Engineering Solutions for Accessing Difficult Targets
Bispecifics & multispecifics
Johnson & Johnson
New Brunswick, NJ
Large pharma
Healthcare company whose Innovative Medicine segment develops antibodies, bispecifics and other medicines.
Talk
Sun Dec 13
2:15pm–2:45pm
Format Matters: Biophysical Characterization and Developability of Complex Biotherapeutics
How a molecule's overall shape changes whether it can be made into a drug, across many measured antibody formats.
Talk
Mon Dec 14
10:55am–11:30am
Jim Huston Science Talent Award and Presentation
Keynote Presentations - Livestream · with Xencor, Dana-Farber Cancer Institute
Chair
Tue Dec 15
8:10am–8:15am
Co-Chairs’ Remarks
Track 1: Advanced In Vivo Approaches to Antibody Discovery · with Genentech
Regeneron
Tarrytown, NY
Large pharma
Biotechnology company that discovers, develops and markets antibody medicines, including bispecific antibodies, using its VelocImmune mouse platform.
Talk
Sun Dec 13
3:45pm–4:15pm
From Molecule Design to Approved Regimens: A Clinical Pharmacology Perspective on Dose Selection for Next-Generation Biologics
How measurements of drug levels and effects in the body guide the first human dose and the final approved dosing schedule.
Talk
Mon Dec 14
5:15pm–5:45pm
Targeting IgE Responses
Track 2: Engineering Solutions for Accessing Difficult Targets
Beyond oncology
Chair
Wed Dec 16
8:10am–8:15am
Co-Chairs’ Remarks
Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs · with Rondo Therapeutics
Twist Bioscience
South San Francisco, CA
Reagents & consumablesEvent partner
Synthetic DNA company whose biopharma unit provides antibody libraries and antibody discovery and optimization services.
Booth
Exhibiting at Booth 200
Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm
Talk
Mon Dec 14
12:15pm–1:15pm
Scaling Wet-Lab Validation for AI-based Biologic Discovery
Why lab testing has become the bottleneck for AI antibody design, and how a shared model platform from Eli Lilly connects to it.
with Eli Lilly
AI & computational designAntibody discovery
Talk
Tue Dec 15
1:40pm–2:00pm
Screening in the Format You’ll Develop In: Cell-Free Expression of Full-Length IgG
Making full-length antibodies without cells at screening scale, and how their binding compares with the same antibodies made in mammalian cells.
Antibody discovery
Talk
Wed Dec 16
7:30am–8:00am
Engineering for Better Bispecifics: Introducing the B-Body® Platform
A two-target antibody design meant to assemble reliably, avoiding low yields and hard purification when production scales up.
Bispecifics & multispecificsDevelopability & CMC
Academic
Public research university in Ann Arbor, Michigan.
Chair
Sun Dec 13
1:00pm–1:15pm
Co-Chairs’ Remarks- Engineering Considerations for Candidate Selection and Developability
Workshop 2: Engineering Considerations for Candidate Selection and Developability · with Atlas Venture NewCo
Talk
Tue Dec 15
3:00pm–3:30pm
Dual-targeted Oligoshuttles Mediate Efficient Reduction of Neuronal Gene Expression after Peripheral Administration
Antibodies that grab two receptors to cross into the brain and deliver gene-silencing strands into nerve cells.
Bispecifics & multispecifics
Biotech
Develops multispecific antibody therapeutics and antibody–drug conjugates using its Azymetric bispecific and other protein engineering platforms.
Talk
Sun Dec 13
1:45pm–2:15pm
Engineering Conditional Co-stimulation: Key Considerations for Developing Next-Generation T Cell Engagers
What to get right, from target choice to safety testing, when building T-cell-recruiting antibodies with a built-in second signal.
Bispecifics & multispecifics
Talk
Wed Dec 16
8:45am–9:15am
Engineering Trispecific T Cell Engagers (TriTCEs) For Optimal Activity and Developability
Antibodies that bind three things at once to give T cells an extra activating signal inside solid tumors.
Developability & CMC
Asimov
Boston, MA
CRO & CDMOBronze sponsor
Offers CHO cell line development services built on its CHO Edge expression system and genetic design software for biologics manufacturing.
Booth
Exhibiting at Booth 101
Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm
Talk
Mon Dec 14
1:45pm–2:15pm
An AI-Driven Approach to CHO Biologics Production
How a platform combining AI and synthetic biology builds high-yield Chinese hamster ovary cell lines for antibodies, including bispecific and multispecific ones.
Developability & CMCAI & computational design
ATUM
Newark, CA
Reagents & consumablesBronze sponsor
Provides gene synthesis, protein expression and the Leap-In transposase system for stable cell line development.
Booth
Exhibiting at Booth 309
Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm
Talk
Mon Dec 14
1:15pm–1:45pm
Accelerating Lead Generation: An Integrated End-to-End Antibody Discovery and Engineering Pipeline
Moving from mouse immunization to humanized antibodies, then testing how well the leads convert into two-target formats, as one quick pipeline.
Antibody discovery
CRO & CDMOAssociate sponsor
Contract research, development and manufacturing organization in India offering antibody discovery and biologics development and manufacturing.
Booth
Exhibiting at Booth 421
Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm
Talk
Tue Dec 15
1:20pm–1:40pm
Discover, Express, De-Risk: Accelerating Antibodies from Single B Cells to Lead Candidates
Linking single B-cell sorting to fast antibody production and lab tests that flag molecules likely to cause problems during development.
Antibody discoveryDevelopability & CMC
Primrose Bio
San Diego, CA
CRO & CDMOSilver sponsor
Licenses its Pseudomonas-based Pfenex expression technology and provides strain engineering to take protein therapeutics from sequence to a GMP-ready process.
Booth
Exhibiting at Booth 305
Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm
Talk
Tue Dec 15
12:05pm–12:35pm
From Hit Selection to Functional Testing: Reducing Expression Bottlenecks in Antibody Discovery
Producing antibody fragments earlier in a different host organism, so more hits can actually be purified and tested.
Antibody discoveryDevelopability & CMC
Reagents & consumablesSilver sponsor
Supplies Optimum Growth shake flasks, well plates and filter vials for transient and stable cell culture and sample preparation.
Booth
Exhibiting at Booth 218
Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm
Talk
Mon Dec 14
12:15pm–1:15pm
Tips and Tricks in Speeding up Transient HEK293 and Transient/Stable CHO from 96 Well, 24 Well, 6 Well, 125mL-7L Optimum Growth Flasks
Practical ways to get more protein out of small-volume cell cultures, from well plates up to multi-liter flasks.
Developability & CMC

Explore the full Antibody Engineering 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in San Diego. Leave your work email and we’ll be in touch.

Privacy

Download the full Antibody Engineering 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers in developability & CMC

Tell us what you sell and we’ll find the people at organizations working on developability & CMC most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse Antibody Engineering 2026 by

Exhibit hall

Not affiliated with or endorsed by Antibody Engineering & Therapeutics, its organizers or The Antibody Society. Submit a correction